Baker Bros. Advisors GRAL Position
Active6-Fund ConvergenceBaker Bros. Advisors increased their position in GRAIL, Inc. (GRAL) in Q4 2025, holding $178.5M worth of shares across 2,085,333 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
GRAL is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 18.0% of float with 2.9 days to cover, indicating significant bearish positioning against Baker Bros.'s long thesis.
About GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Full company profile →Short Interest
18.0%
2.9 days to cover
Baker Bros. Advisors GRAL Position History
Frequently Asked Questions
Does Baker Bros. Advisors own GRAL?
Yes. As of Q4 2025, Baker Bros. Advisors holds 2,085,333 shares of GRAIL, Inc. (GRAL) valued at $178.5M. This data comes from their SEC 13F filing.
How many hedge funds own GRAL?
6 specialist biotech hedge funds currently hold GRAL, including Deep Track Capital, RA Capital Management, Perceptive Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy GRAL?
Baker Bros. Advisors's position in GRAL was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's GRAL position increasing or decreasing?
Baker Bros. Advisors increased their GRAL position in the most recent quarter, adding 455,208 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GRALCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →